Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).
暂无分享，去创建一个
R. López | R. García-Carbonero | E. Díaz-Rubio | E. Aranda | C. Guillén | M. Safont | J. Sastre | E. G. Flores | P. García-Alfonso | J. Viéitez | B. Suárez | S. Calle | G. Aldana | J. J. Reina-Zoilo | B. G. Paredes | E. M. Castro | A. S. Salvia | M. A. Gómez-España | M. Fernández | A. L. Muñoa